Genomic Landscape of EGFR Mutant NSCLC Prior to Erlotinib and at the Time of Disease Progression

Inclusion Criteria

• •Patient Selection
• •Diagnosis of metastatic stage IIIB/IV lung adenocarcinoma
• •Presence of known sensitizing mutations in EGFR TK domain
• •Consented to HRPO# 201305031 ("Tissue and Blood Acquisition for Genomic Analysis and Collection of Health Information from Patients with Thoracic Malignancies, Suspected -Thoracic Malignancies, or Mesothelioma")
• •Treatment with standard of care erlotinib
• •At least 18 years of age